The 2019 CRO & CMO Summit is a half-day program designed specifically for those planning and conducting clinical trials or those who are seeking advice when selecting outsourced providers.
Location: West Pharmaceutical Services, Inc. in Exton, PA
Date: Friday November 22, 2019
Time: 8:00 - 11:30 AM
Who Should Attend:
· Individuals interested in becoming involved in a strategic partnership with a CRO or CMO in the next 12 to 18 months
· Biotech, pharma, medical device or diagnostic companies planning a clinical trial
· Individuals who have secured a CRO and CMO and the relationship has not been successful
............
Agenda
............
8 – 8:30 AM Registration and networking
8:30 – 8:45 AM Welcome
- Cindy Reiss-Clark, Vice President, General Manager, Biologics, West Pharmaceutical Services
8:45 – 9:15 AM Keynote - The Next Generation of T Cell Immunotherapy
- Usman “Oz” Azam, MD, President & CEO, Tmunity Therapeutics
9:15 – 9:30 AM Break
9:30 – 10:30 AM Panel Discussion - Deeper Dive Into Innovative Therapies: Clinical Trials and Manufacturing
- Heather D. Malicki, Ph.D., Executive Director, Analytical Development and Testing Technologies, WuXi Advanced Therapies
- Erin Van Winkle, Senior Director, Clinical Programs, Adaptimmune
- Alex Lyness, Ph.D., Manager, Research & Technology, West Pharmaceutical Services
- Moderator: Rachel Kane, Senior Manager, Navigate Corporation
10:30 – 11:30 AM Networking and Lab Tour
Speaker Details
Keynote: Usman “Oz” Azam, MD, President & CEO, Tmunity Therapeutics
Dr. Azam is Tmunity’s President and CEO. Prior to joining Tmunity in 2016, he was the Head of the Cell & Gene Therapies Unit at Novartis Pharmaceuticals and was a member of the Pharmaceutical Executive Committee. Previous roles at Novartis included Head of Global Medical Affairs & HEOR General Medicines, Chief Scientific Officer and Head of US Clinical Development & Medical Affairs and Global Head Regulatory Affairs for the Neurosciences & Ophthalmic Franchise. Prior to Novartis, he was the CEO of Novaccel Therapeutics LLC, a company he founded focusing on accelerating translational medicine assets. Dr. Azam also held roles at Aspreva Pharmaceutics Inc and J&J. He started his life sciences career with Warner Lambert-Parke Davis in 1998. Dr. Azam is a member of the Board of Directors of the Alliance for Regenerative Medicine. Dr. Azam has a BSc and MD from the University of Liverpool.
